Drug Profile
Research programme: T-cell therapies - BioNTech/CRISPR Therapeutics
Latest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator CRISPR Therapeutics; Neon Therapeutics
- Developer BioNTech; CRISPR Therapeutics
- Class Gene therapies; T lymphocyte cell therapies
- Mechanism of Action Immunomodulators; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer